Literature DB >> 28283200

Pharmacological Targeting of the Host-Pathogen Interaction: Alternatives to Classical Antibiotics to Combat Drug-Resistant Superbugs.

Jason Munguia1, Victor Nizet2.   

Abstract

The rise of multidrug-resistant pathogens and the dearth of new antibiotic development place an existential strain on successful infectious disease therapy. Breakthrough strategies that go beyond classical antibiotic mechanisms are needed to combat this looming public health catastrophe. Reconceptualizing antibiotic therapy in the richer context of the host-pathogen interaction is required for innovative solutions. By defining specific virulence factors, the essence of a pathogen, and pharmacologically neutralizing their activities, one can block disease progression and sensitize microbes to immune clearance. Likewise, host-directed strategies to boost phagocyte bactericidal activity, enhance leukocyte recruitment, or reverse pathogen-induced immunosuppression seek to replicate the success of cancer immunotherapy in the field of infectious diseases. The answer to the threat of multidrug-resistant pathogens lies 'outside the box' of current antibiotic paradigms.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  antibiotic resistance; bacterial infections; immunotherapy; macrophages; neutrophils; virulence factors

Mesh:

Substances:

Year:  2017        PMID: 28283200      PMCID: PMC5750058          DOI: 10.1016/j.tips.2017.02.003

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  98 in total

1.  Mucosal administration of flagellin protects mice from Streptococcus pneumoniae lung infection.

Authors:  Natalia Muñoz; Laurye Van Maele; Juan M Marqués; Analía Rial; Jean-Claude Sirard; José A Chabalgoity
Journal:  Infect Immun       Date:  2010-07-19       Impact factor: 3.441

2.  Polyvalent inhibitors of anthrax toxin that target host receptors.

Authors:  Saleem Basha; Prakash Rai; Vincent Poon; Arundhati Saraph; Kunal Gujraty; Mandy Y Go; Skanda Sadacharan; Mia Frost; Jeremy Mogridge; Ravi S Kane
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-28       Impact factor: 11.205

3.  A new pharmacological agent (AKB-4924) stabilizes hypoxia inducible factor-1 (HIF-1) and increases skin innate defenses against bacterial infection.

Authors:  Cheryl Y M Okumura; Andrew Hollands; Dan N Tran; Joshua Olson; Samira Dahesh; Maren von Köckritz-Blickwede; Wdee Thienphrapa; Courtney Corle; Seung Nam Jeung; Anna Kotsakis; Robert A Shalwitz; Randall S Johnson; Victor Nizet
Journal:  J Mol Med (Berl)       Date:  2012-02-28       Impact factor: 4.599

4.  Disarming bacterial virulence through chemical inhibition of the DNA binding domain of an AraC-like transcriptional activator protein.

Authors:  Ji Yang; Dianna M Hocking; Catherine Cheng; Con Dogovski; Matthew A Perugini; Jessica K Holien; Michael W Parker; Elizabeth L Hartland; Marija Tauschek; Roy M Robins-Browne
Journal:  J Biol Chem       Date:  2013-09-09       Impact factor: 5.157

5.  Anthrax lethal factor inhibition.

Authors:  W L Shoop; Y Xiong; J Wiltsie; A Woods; J Guo; J V Pivnichny; T Felcetto; B F Michael; A Bansal; R T Cummings; B R Cunningham; A M Friedlander; C M Douglas; S B Patel; D Wisniewski; G Scapin; S P Salowe; D M Zaller; K T Chapman; E M Scolnick; D M Schmatz; K Bartizal; M MacCoss; J D Hermes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-23       Impact factor: 11.205

6.  Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus.

Authors:  George Sakoulas; Cheryl Y Okumura; Wdee Thienphrapa; Joshua Olson; Poochit Nonejuie; Quang Dam; Abhay Dhand; Joseph Pogliano; Michael R Yeaman; Mary E Hensler; Arnold S Bayer; Victor Nizet
Journal:  J Mol Med (Berl)       Date:  2013-12-03       Impact factor: 4.599

7.  Resolvin D4 stereoassignment and its novel actions in host protection and bacterial clearance.

Authors:  Jeremy W Winkler; Sarah K Orr; Jesmond Dalli; Chien-Yee C Cheng; Julia M Sanger; Nan Chiang; Nicos A Petasis; Charles N Serhan
Journal:  Sci Rep       Date:  2016-01-08       Impact factor: 4.379

8.  Failure to induce IFN-β production during Staphylococcus aureus infection contributes to pathogenicity.

Authors:  Amber Kaplan; Jun Ma; Pierre Kyme; Andrea J Wolf; Courtney A Becker; Ching Wen Tseng; George Y Liu; David M Underhill
Journal:  J Immunol       Date:  2012-09-24       Impact factor: 5.422

9.  Immunostimulation with macrophage-activating lipopeptide-2 increased survival in murine pneumonia.

Authors:  Katrin Reppe; Thomas Tschernig; Anke Lührmann; Vincent van Laak; Karsten Grote; Maren V Zemlin; Birgitt Gutbier; Holger C Müller; Mischo Kursar; Hartwig Schütte; Simone Rosseau; Reinhard Pabst; Norbert Suttorp; Martin Witzenrath
Journal:  Am J Respir Cell Mol Biol       Date:  2008-10-17       Impact factor: 6.914

10.  Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment.

Authors:  Anastasia Nijnik; Laurence Madera; Shuhua Ma; Matthew Waldbrook; Melissa R Elliott; Donna M Easton; Matthew L Mayer; Sarah C Mullaly; Jason Kindrachuk; Håvard Jenssen; Robert E W Hancock
Journal:  J Immunol       Date:  2010-01-27       Impact factor: 5.422

View more
  30 in total

1.  A high-throughput system to identify inhibitors of Candidatus Liberibacter asiaticus transcription regulators.

Authors:  Melanie J Barnett; David E Solow-Cordero; Sharon R Long
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-19       Impact factor: 11.205

2.  Resolvin D2 promotes host defense in a 2 - hit model of sepsis with secondary lung infection.

Authors:  J M Walker; P Y Kadiyam Sundarasivarao; J M Thornton; K Sochacki; A Rodriguez; B W Spur; N K Acharya; K Yin
Journal:  Prostaglandins Other Lipid Mediat       Date:  2022-01-08       Impact factor: 3.072

Review 3.  Targeting the Holy Triangle of Quorum Sensing, Biofilm Formation, and Antibiotic Resistance in Pathogenic Bacteria.

Authors:  Ronit Vogt Sionov; Doron Steinberg
Journal:  Microorganisms       Date:  2022-06-16

Review 4.  Antibacterial effects of vanilla ingredients provide novel treatment options for infections with multidrug-resistant bacteria - A recent literature review.

Authors:  Noah A Maisch; Stefan Bereswill; Markus M Heimesaat
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2022-09-23

5.  Coagulase-Negative Staphylococcal Strain Prevents Staphylococcus aureus Colonization and Skin Infection by Blocking Quorum Sensing.

Authors:  Alexandra E Paharik; Corey P Parlet; Nadjali Chung; Daniel A Todd; Emilio I Rodriguez; Michael J Van Dyke; Nadja B Cech; Alexander R Horswill
Journal:  Cell Host Microbe       Date:  2017-11-30       Impact factor: 21.023

6.  The Accidental Orthodoxy of Drs. Mueller and Hinton.

Authors:  Victor Nizet
Journal:  EBioMedicine       Date:  2017-07-04       Impact factor: 8.143

7.  A Red Blood Cell Membrane-Camouflaged Nanoparticle Counteracts Streptolysin O-Mediated Virulence Phenotypes of Invasive Group A Streptococcus.

Authors:  Tamara Escajadillo; Joshua Olson; Brian T Luk; Liangfang Zhang; Victor Nizet
Journal:  Front Pharmacol       Date:  2017-07-18       Impact factor: 5.810

8.  Pyrimidine synthesis inhibition enhances cutaneous defenses against antibiotic resistant bacteria through activation of NOD2 signaling.

Authors:  Samreen Jatana; Craig R Homer; Maria Madajka; András K Ponti; Amrita Kabi; Francis Papay; Christine McDonald
Journal:  Sci Rep       Date:  2018-06-07       Impact factor: 4.379

9.  Lipoxin A4 promotes reduction and antibiotic efficacy against Pseudomonas aeruginosa biofilm.

Authors:  J M Thornton; J M Walker; P Y Kadiyam Sundarasivarao; B W Spur; A Rodriguez; K Yin
Journal:  Prostaglandins Other Lipid Mediat       Date:  2020-11-03       Impact factor: 3.072

10.  An Antivirulence Approach for Preventing Cryptococcus neoformans from Crossing the Blood-Brain Barrier via Novel Natural Product Inhibitors of a Fungal Metalloprotease.

Authors:  Phylicia A Aaron; Kiem Vu; Angie Gelli
Journal:  mBio       Date:  2020-07-21       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.